GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: After the adoption of a resolution to spin off Vitrolife’s (STO:VITR) transplantation business, Vitrolife’s Board has set new financial objectives for the company.
Vitrolife’s new financial objectives are as follows:
Vitrolife’s Board considers that Vitrolife should have a strong capital base in order to enable continued high growth, both organically and through acquisitions. The company’s net debt in relation to EBITDA should normally not exceed 3 times. Vitrolife’s Board targets a profitable growth. The objective for Vitrolife’s growth over a three year period is an increase in sales by an average of 20 percent per year, with an operating margin of 15 percent.